Antonio Antón

5.1k total citations
61 papers, 2.1k citations indexed

About

Antonio Antón is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Antonio Antón has authored 61 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 19 papers in Cancer Research. Recurrent topics in Antonio Antón's work include Cancer Treatment and Pharmacology (22 papers), Breast Cancer Treatment Studies (16 papers) and Colorectal Cancer Treatments and Studies (14 papers). Antonio Antón is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Breast Cancer Treatment Studies (16 papers) and Colorectal Cancer Treatments and Studies (14 papers). Antonio Antón collaborates with scholars based in Spain, United Kingdom and Italy. Antonio Antón's co-authors include Alfredo Carrato, Rosa Güell, Á. Artal, Rafael Rosell, J. Sanchís, Bartomeu Massutí, I. Barneto, Roberto Pazo-Cid, M. Lomas and Joaquín Montalar and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Antonio Antón

59 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antonio Antón Spain	21	1.4k	1.0k	451	339	289	61	2.1k
Yuan Liu United States	25	708 0.5×	1.4k 1.3×	350 0.8×	354 1.0×	137 0.5×	145	2.1k
Mario Airoldi Italy	24	1.0k 0.7×	498 0.5×	224 0.5×	878 2.6×	615 2.1×	142	1.9k
Wei Chua Australia	23	1.2k 0.9×	447 0.4×	512 1.1×	348 1.0×	45 0.2×	80	1.8k
Diane Savarese United States	16	576 0.4×	526 0.5×	184 0.4×	218 0.6×	48 0.2×	24	1.2k
Kosuke Kashiwabara Japan	18	463 0.3×	457 0.4×	137 0.3×	258 0.8×	26 0.1×	95	1.4k
Agnès J. van de Wouw Netherlands	21	1.3k 1.0×	511 0.5×	554 1.2×	133 0.4×	98 0.3×	56	1.7k
János Strausz Hungary	15	895 0.7×	1.8k 1.7×	139 0.3×	381 1.1×	19 0.1×	54	2.2k
Erkan Topkan Türkiye	21	568 0.4×	492 0.5×	140 0.3×	235 0.7×	157 0.5×	129	1.2k
Yun‐Gyoo Lee South Korea	15	436 0.3×	430 0.4×	123 0.3×	112 0.3×	67 0.2×	72	942
Emmanuel Gabriel United States	23	958 0.7×	525 0.5×	243 0.5×	850 2.5×	15 0.1×	121	1.9k

Countries citing papers authored by Antonio Antón

Since Specialization

Citations

This map shows the geographic impact of Antonio Antón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Antón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Antón more than expected).

Fields of papers citing papers by Antonio Antón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Antón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Antón. The network helps show where Antonio Antón may publish in the future.

Co-authorship network of co-authors of Antonio Antón

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Antón. A scholar is included among the top collaborators of Antonio Antón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Antón. Antonio Antón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Martínez-Jáñez, Noelia, Fernando Henao, Luís Manso, et al.. (2023). Abstract P4-01-28: PALBOSPAIN: OBSERVATIONAL ANALYSIS OF FIRST-LINE THERAPY WITH PALBOCICLIB IN PATIENTS WITH HR+/HER2- METASTATIC BREAST CANCER (MBC) IN REAL-LIFE CONDITIONS. Cancer Research. 83(5_Supplement). P4–1. 3 indexed citations

Ciruelos, Eva, Álvaro Montaño, César A. Rodríguez, et al.. (2020). Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2‐positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012‐07). European Journal of Cancer Care. 29(4). e13253–e13253. 7 indexed citations

Fudio, Salvador, Josep Tabernero, Vivek Subbiah, et al.. (2020). Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis. Cancer Chemotherapy and Pharmacology. 87(1). 113–124. 3 indexed citations

Antón, Antonio, Isabel Garau, N. Afonso, et al.. (2018). Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study. Clinical Breast Cancer. 19(2). 105–112. 11 indexed citations

García‐Foncillas, Jesús, Josep Tabernero, Élena Elez, et al.. (2018). Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. British Journal of Cancer. 119(12). 1464–1470. 59 indexed citations

Puértolas, Teresa, et al.. (2016). Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. Molecular and Clinical Oncology. 5(4). 458–462. 23 indexed citations

Pallero, Mercedes, Rosa Güell, Caridad Pontes, et al.. (2014). Ambulatory adaptation to noninvasive ventilation in restrictive pulmonary disease: A randomized trial with cost assessment. Respiratory Medicine. 108(7). 1014–1022. 16 indexed citations

Pazo-Cid, Roberto & Antonio Antón. (2012). Advanced HER2-positive gastric cancer: Current and future targeted therapies. Critical Reviews in Oncology/Hematology. 85(3). 350–362. 51 indexed citations

Sánchez‐Rovira, Pedro, Antonio Antón, Agustí Barnadas, et al.. (2012). Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study. Clinical & Translational Oncology. 14(6). 430–436. 10 indexed citations

10.

Martín, Miguel, Aňa Lluch, Amparo Ruı́z, et al.. (2012). Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial.. Journal of Clinical Oncology. 30(15_suppl). 1001–1001. 1 indexed citations

11.

Antón, Antonio, Agustí Barnadas, Jesús Florián, et al.. (2011). Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000–02 phase II study. Clinical & Translational Oncology. 13(4). 281–286. 3 indexed citations

12.

Abad, Albert, Bartomeu Massutí, Antonio Antón, et al.. (2008). Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta Oncologica. 47(2). 286–292. 14 indexed citations

13.

Ruı́z, Amparo, Miguel Martín, Antonio Antón, et al.. (2006). Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM). Breast Cancer Research and Treatment. 101(2). 215–223. 42 indexed citations

14.

Martínez‐Trufero, Javier, Juan Lao, Teresa Puértolas, et al.. (2005). Serum Markers and Prognosis in Locally Advanced Breast Cancer. Tumori Journal. 91(6). 522–530. 15 indexed citations

15.

Abad, Albert, Alfredo Carrato, Matilde Navarro, et al.. (2005). Two Consecutive Phase II Trials of Biweekly Oxaliplatin plus Weekly 48-Hour Continuous Infusion of Nonmodulated High-Dose 5-Fluorouracil as First-Line Treatment for Advanced Colorectal Cancer. Clinical Colorectal Cancer. 4(6). 384–389. 7 indexed citations

16.

García‐Estévez, Laura, Antonio Antón, Jesús Florián, et al.. (2003). Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.. PubMed. 9(2). 686–92. 61 indexed citations

17.

Antón, Antonio, et al.. (2003). Acute Physiologic Effects of Nasal and Full-Face Masks During Noninvasive Positive-Pressure Ventilation in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Respiratory Care. 48(10). 922–925. 29 indexed citations

18.

Maurel, Joan, Teresa Puértolas, Antonio Antón, et al.. (2001). Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anti-Cancer Drugs. 12(9). 713–717. 20 indexed citations

19.

Maurel, Joan, Javier Martínez‐Trufero, Á. Artal, et al.. (2000). Prognostic impact of bulky mediastinal lymph nodes (N2>2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy. Lung Cancer. 30(2). 107–116. 9 indexed citations

20.

Aranda, Enrique, et al.. (1994). Phase II Study with Iododoxorubicin in Measurable Advanced Colorectal Adenocarcinoma. Effective Rescue Using Weekly High-Dose 5-Fluorouracil (WFU). Tumori Journal. 80(2). 124–127. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact